Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy

American Journal of Hematology

Volumn 91, Issue 10, 2016, Pages 1002-1007

  Xiao, Daphne Y ^a,b   Luo, Suhong ^a,b   O'Brian, Katiuscia ^a,b   Ganti, Arun ^c   Riedell, Peter ^b   Sanfilippo, Kristen M ^a,b   Lynch, Ryan C ^d   Liu, Weijian ^a   Carson, Kenneth R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG TOLERANCE; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SARCOPENIA; UNITED STATES;

EID: 84990192257     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24465     Document Type: Article

References (35)

1. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:265–276.
2. Swerdlow S, Campo E, Harris N, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; 2008.
3. Lanic H, Kraut-tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 2014;55:817–823.
4. Nakamura N, Hara T, Shibata Y, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol 2015;94:2043–2053.
5. Go S, Park MJ, Song H, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle 2016 DOI:10.1002/jcsm.12115.
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
7. Epelbaum R, Haim N, Ben-Shahar M, et al. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988;24:533–538.
8. Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990;8:963–977.
9. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol 1993;4:651–656.
10. Prado CMM, Baracos VE, Mccargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3269.
11. Prado CMM, Baracos VE, Mccargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920–2926.
12. Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594–1598.
13. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695–708.
14. Zelenetz A. Non-Hodgkin Lymphomas. Accessed from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases: Differing perspectives. J Clin Epidemiol 1993;46:1075–1079.
16. Smith TJ, Bolke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2015;33:3199–3212.
17. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
18. WHO Expert Commitee Physical status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995;854:1–452.
19. Dubois D, Dubois E. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;17:863–871.
20. Hryniuk W, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935–1937.
21. Lyman GH, Dale DC, Friedberg J, et al. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: A nationwide study. J Clin Oncol 2004;22:4302–4311.
22. Mourtzakis M, Prado CMM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997–1006.
23. Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–1547.
24. Caram MV, Bellile EL, Englesbe MJ, et al. Sarcopenia is associated with autologous transplant-related outcomes in patients with lymphoma. Leuk Lymphoma 2015;56:2855–2862.
25. Lyman G, Lyman C, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.
26. Ganti A, Liu W, Luo S., et al. Impact of BMI on incidence of febrile neutropenia and treatment-related mortality in United States veterans with diffuse large B-cell lymphoma receiving R-CHOP. Br J Haematol 2013;167:699–702.
27. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review. J Clin Oncol 2007;25:3158–3167.
28. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
29. Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol 2012;30:1829–1834.
30. Bahat G, Saka B, Tufan F, et al. Prevalence of sarcopenia and its association with functional and nutritional status among male residents in a nursing home in Turkey. Aging Male 2010;13:211–214.
31. Prado CMM, Maia YLM, Ormsbee M, et al. Assessment of nutritional status in cancer – The relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 2013;13:1197–1203.
32. Cosolo W, Morgan D, Seeman E, et al. Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs 1994;3:293–297.
33. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634–641.
34. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
35. Cruz-Jentoft A, Baeyens J, Bauer J, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423.